Clinical Trial

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Study acronym: AK112-311
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-05.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT07010263
Lead Sponsor Akeso
Conditions Small Cell Lung Cancer
Enrollment 560 participants
Start Date 2025-06-13
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05